Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Raikar, G. V.
Right arrow Articles by Donohue, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Raikar, G. V.
Right arrow Articles by Donohue, J. H.

Annals of Surgical Oncology, Vol 3, Issue 5 470-475, Copyright © 1996 by Society of Surgical Oncology

ARTICLES

Cost-effective analysis of surgical palliation versus endoscopic stenting in the management of unresectable pancreatic cancer

G. V. Raikar, M. M. Melin, A. Ress, S. Z. Lettieri, J. J. Poterucha, D. M. Nagorney and J. H. Donohue
Department of Surgery, Mayo Clinic, Rochester, Minnesota 55905, USA.

BACKGROUND: Ductal carcinoma of the pancreas is unresectable for cure in the majority of patients. We reviewed our results and cost effectiveness of surgical and endoscopic biliary bypass for unresectable pancreatic cancer to evaluate the comparable outcomes. METHODS: Between 1990 and 1992, 136 patients were managed operatively or endoscopically for pancreatic carcinoma. Excluding potentially curative resections and patients without follow-up, 34 patients endoscopically stented and 32 patients surgically bypassed were evaluated. RESULTS: Mean patient age was older (72.1 vs. 69.3 years) but average performance status was comparable (0.8 vs. 0.9 Eastern Cooperative Oncology Group grading) in the medical treatment group. The initial hospital stay was significantly longer for surgical patients (mean 14 vs. 7 days, p < 0.001), with higher average charges ($18,325 vs. $9,663). Twelve stented patients required rehospitalization (average charge of $4,029), and eight surgical patients were readmitted (average charge of $6,776). An average of 1.7 stent changes (average charge $1,190) were required. Mean survival was longer for the stented group (9.7 vs. 7.3 months, p = 0.13). CONCLUSIONS: Endoscopic stenting for unresectable pancreatic cancer provides equivalent duration of survival at reduced cost and shorter hospital stay, although subsequent stent changes are necessary. When curative resection is not possible, endoscopic biliary drainage should be considered a good first choice for palliative management.


This article has been cited by other articles:


Home page
 Ann. Surg. Oncol.Home page
R. S. Date and A. K Siriwardena
Editorial: Laparoscopic Biliary Bypass and Current Management Algorithms for the Palliation of Malignant Obstructive Jaundice
Ann. Surg. Oncol., September 1, 2004; 11(9): 815 - 817.
[Full Text] [PDF]

Home page
 NEJMHome page
N. C. Fisher, S. G. Putnam, R. E. Schwarz, J. V. Dam, and W. R. Brugge
Endoscopy
N. Engl. J. Med., April 20, 2000; 342(16): 1219 - 1221.
[Full Text]

Home page
 NEJMHome page
W. R. Brugge and J. V. Dam
Pancreatic and Biliary Endoscopy
N. Engl. J. Med., December 9, 1999; 341(24): 1808 - 1816.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the Society of Surgical Oncology.